{
    "clinical_study": {
        "@rank": "53666", 
        "arm_group": [
            {
                "arm_group_label": "ARCO treatment", 
                "arm_group_type": "Experimental", 
                "description": "Patients in this treatment arm will receive on Day 0 a single dose of standard treatment of artemisinin/naphthoquine (in a fixed oral dose of ARCO tablets). Treatment will be given under supervision."
            }, 
            {
                "arm_group_label": "Eurartesim treatment", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients in this treatment arm will receive a dose of  dihydroartemisinin/piperaquine phosphate (in a fixed oral dose of Eurartesim tablets) over three days (0,1,2). Treatment will be given under supervision."
            }
        ], 
        "brief_summary": {
            "textblock": "Phase IV, single center, 2 arms randomized controlled, open label study. Study will be\n      conducted over a period of 42 days to determine the safety, tolerability, pharmacokinetics\n      and efficacy of ARCO."
        }, 
        "brief_title": "Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Plasmodium Falciparum", 
            "Malaria, Falciparum"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Malaria", 
                "Malaria, Falciparum"
            ]
        }, 
        "detailed_description": {
            "textblock": "Evaluation of safety and tolerability of the administration of ARCO and Eurartesim in terms\n      of blood biochemistry, full blood count, ECG assessments, vital signs and adverse events\n      profile in patients with uncomplicated P. falciparum malaria. Dihydroartemisinin/piperaquine\n      will be used as comparator."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Written informed consent, in accordance with local practice, provided by patient, for\n             children it will provided by either parents or legal representative and in addition\n             children will provide assent.\n\n          2. Male or female patients between the age of 6 and 60 years (both inclusive)\n\n          3. Body weight between 20 kg and 90 kg (both inclusive)\n\n          4. Presence of mono-infection with P. falciparum (1,000 to 100,000 asexual count/\u00b5l of\n             blood) microscopically confirmed.\n\n          5. Fever, as defined by axillary temperature \u2265 37.5\u00b0C to \u2264 39.5\u00b0C\n\n          6. Ability to swallow oral medication\n\n          7. Ability and willingness to adhere to all study procedures and access health\n             facilities.\n\n          8. Agree to undergo study related procedures including being hospitalized for minimum of\n             3 days (0,1 and 2), and a follow up of up to 42 days.\n\n        Exclusion Criteria:\n\n          1. Patients with signs and symptoms of severe/complicated malaria as described in the\n             WHO guideline(Third Edition 2012) for management of severe malaria(6)(Appendix 1)\n\n          2. Mixed Plasmodial infection.\n\n          3. Severe vomiting, defined as more than three times in the 24 hours prior to inclusion\n             in the study or inability to tolerate oral treatment.\n\n          4. Severe diarrhoea defined as 3 or more watery stools per day.\n\n          5. Presence of other serious or chronic clinical condition requiring hospitalization.\n\n          6. Known history or evidence of clinically significant disorders such as cardiovascular\n             (including arrhythmia, QTcF or QTcB interval greater than or equal to 450 msec),\n             respiratory (including active tuberculosis), history of jaundice, hepatic, renal,\n             gastrointestinal, immunological, neurological (including auditory), endocrine,\n             infectious, malignancy, psychiatric, history of convulsions or other abnormality\n             (including head trauma).\n\n          7. Family history of sudden death or of congenital prolongation of the QT interval or\n             any other clinical condition known to prolong the QT interval.\n\n          8. Known congenital prolongation of the QT-interval or any clinical condition known to\n             prolong the QT interval.\n\n          9. History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia.\n\n         10. Any predisposing cardiac conditions for arrhythmia such as severe hypertension, left\n             ventricular hypertrophy (including hypertrophic cardiomyopathy) or congestive cardiac\n             failure accompanied by reduced left ventricle ejection fraction.\n\n         11. Electrolyte disturbances, particularly hypokalaemia, hypocalcaemia or\n             hypomagnesaemia.\n\n         12. Any treatment which can induce a lengthening of QT interval, such as:\n\n             i. Antiarrhythmics (e.g. amiodarone, disopyramide, dofetilide, ibutilide,\n             procainamide, quinidine, hydroquinidine, sotalol) ii. Neuroleptics (e.g.\n             phenothiazines, sertindole, sultopride, chlorpromazine, haloperidol, mesoridazine,\n             pimozide, or thioridazine) iii. Antidepressive agents, certain antimicrobial agents,\n             including agents of the following classes macrolides (e.g. erythromycin,\n             clarithromycin), fluoroquinolones (e.g. moxifloxacin, sparfloxacin), imidazole and\n             triazole antifungal agents, and also pentamidine and saquinavir iv. Certain\n             non-sedating antihistamines (e.g. terfenadine, astemizole, mizolastine), cisapride,\n             droperidol, domperidone, bepridil, diphemanil, probucol, levomethadyl, methadone,\n             vinca alkaloids, arsenic trioxide\n\n         13. Known history of hypersensitivity, allergic or adverse reactions to artemisinin\n             containing compounds, piperaquine or naphthoquine or to any of the excipients\n             contained in ARCO and Eurartesim.\n\n         14. Antimalarial treatment with different antimalarial drugs as follows i.\n             Piperaquine-based compound, mefloquine, naphthoquine or sulphadoxine/pyrimethamine\n             (SP) within the previous 3 months, ii. Amodiaquine or chloroquine within the previous\n             6 weeks, and with quinine, halofantrine, lumefantrine-based compounds and iii. Any\n             other antimalarial treatment, antibiotics with antimalarial activity (including\n             cotrimoxazole, tetracyclines, quinolones and fluoroquinolones, and azithromycin) or\n             any herbal products, within the past 14 days\n\n         15. Have received an investigational drug within the past 6 weeks.\n\n         16. Liver function tests:\n\n             i. If Total Bilirubin is normal, exclude the patient if liver function tests\n             ASAT/ALAT \u2265 3xULN ii. If Total Bilirubin is > 1 and \u2264 1.5xULN, exclude the patient if\n             ASAT/ALAT \u22652xULN.\n\n             iii. Total Bilirubin >1.5xULN\n\n         17. Hb level below 9 g/dL.\n\n         18. Serum creatinine levels more than 2 times the upper limit of normal range in absence\n             of dehydration. In case of important dehydration the creatinine should be lower than\n             2X ULN after oral/parenteral rehydration.\n\n         19. Female patients must be neither pregnant (as demonstrated by a negative serum\n             pregnancy test) nor lactating, and must be willing to take measures not to become\n             pregnant during the study period and safety follow-up period.\n\n         20. Previous participation in any malaria vaccine trial or received malaria vaccine in\n             any other circumstance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01930331", 
            "org_study_id": "IHI"
        }, 
        "intervention": [
            {
                "arm_group_label": "ARCO treatment", 
                "description": "Each tablet of ARCO (artemisinin/naphthoquine) contains 125 mg artemisinin and 50 mg of naphthoquine. The total dose for adults will be 1000mg of artemisinin and 400mg of naphthoquine in a fixed oral dose (ARCO tablet).\nThe regimen for children will be calculated according to the body weight (20mg artemisinin + 8mg naphthoquine per kg body weight in a fixed oral dose(ARCO tablet)).", 
                "intervention_name": "artemisinin/naphthoquine", 
                "intervention_type": "Drug", 
                "other_name": "ARCO\u00ae"
            }, 
            {
                "arm_group_label": "Eurartesim treatment", 
                "description": "Eurartesim (dihydroartemisinin/piperaquine phosphate) is a fixed dose preparation with two dose-strengths (20 mg dihydroartemisinin and 160mg of piperaquine phosphate and 40mg dihydroartemisinin and 320mg of piperaquine phosphate. The regimen for patients with body weight of 36-75kg is three tablets of 40mg dihydroartemisinin and 320mg of piperaquine phosphate once daily for three consecutive days. Those beyond or below this range the regimen will be calculated based on the body weight.", 
                "intervention_name": "dihydroartemisinin/piperaquine phosphate", 
                "intervention_type": "Drug", 
                "other_name": "Eurartesim\u00ae"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Artemisinins", 
                "Dihydroquinghaosu", 
                "Piperaquine", 
                "Artemisinine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Uncomplicated Plasmodium falciparum Malaria", 
        "lastchanged_date": "August 23, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bagamoyo", 
                    "country": "Tanzania", 
                    "zip": "74"
                }, 
                "name": "Ifakara Health Institute"
            }, 
            "investigator": [
                {
                    "last_name": "Salim Abdulla, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Seif Shekalaghe, MD, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Said A Jongo, MD, MMed", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Nahya S Masoud, MD, MMed", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Ali Hamad, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Tanzania"
        }, 
        "number_of_arms": "2", 
        "official_title": "Safety, Tolerability, Pharmacokinetics and Efficacy, Phase Iv, Open Label Study of Fixed Arco\u00ae and Eurartesim\u00ae Therapies in Adults and Children With Uncomplicated P. Falciparum Malaria in Tanzania", 
        "other_outcome": {
            "measure": "Frequency of abnormal safety laboratory parameters (hematology, clinical chemistry, urinalysis and coagulation) and clinical parameters (blood pressure, pulse rate, temperature)", 
            "safety_issue": "Yes", 
            "time_frame": "weekly up to 6 weeks"
        }, 
        "overall_contact": {
            "email": "sabdulla@ihi.or.tz", 
            "last_name": "Salim Abdulla, MD, Phd", 
            "phone": "+255 22 2774756"
        }, 
        "overall_contact_backup": {
            "email": "sshekalaghe@ihi.or.tz", 
            "last_name": "Seif Shekalaghe, MD, Phd", 
            "phone": "+255 686 997713"
        }, 
        "overall_official": {
            "affiliation": "Ifakara Health Institute", 
            "last_name": "Salim Abdulla, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Tanzania: Food & Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of reported non serious and serious adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 6 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01930331"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "For ARCO treatment arm (which will only receive a single dose of ARCO treatment), Holter recording will start 15 minutes before the dose of ARCO, and it will run continuously during 12 hours post dosing.\nFor Eurartesim treatment arm (which will receive three daily doses of Euratertesim treatment), Holter recording will run for 15 minutes before the first dose, and then it will start again 15 minutes before the third dose (last dose) running continuously for 12 hours post dosing.", 
            "measure": "12-lead ECG recordings: Heart rate, PR interval, QRS duration, QT interval, QTc (Fridericia and Bazett corrections), any T wave or U-wave morphology.", 
            "safety_issue": "Yes", 
            "time_frame": "Holter recording will run continuously during 12 hours after the last dose of treatment"
        }, 
        "source": "Ifakara Health Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ifakara Health Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}